Phase II Trial Assessing the Feasibility and Toxicity of Degarelix in Achieving Prostate Downsizing Prior to Treatment With Permanent Seed Prostate Brachytherapy.

Trial Profile

Phase II Trial Assessing the Feasibility and Toxicity of Degarelix in Achieving Prostate Downsizing Prior to Treatment With Permanent Seed Prostate Brachytherapy.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Degarelix (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Aug 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
    • 02 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.
    • 02 Feb 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top